https://atmp.gmp-compliance.org/ https://atmp.gmp-compliance.org/news.html https://atmp.gmp-compliance.org/news/news-detail.html https://atmp.gmp-compliance.org/all-eca-activities.html https://atmp.gmp-compliance.org/members.html https://atmp.gmp-compliance.org/membership/registration.html https://atmp.gmp-compliance.org/faq.html https://atmp.gmp-compliance.org/about-us-contact.html https://atmp.gmp-compliance.org/imprint.html https://atmp.gmp-compliance.org/privacy-policy.html https://atmp.gmp-compliance.org/news/news-detail/what-are-the-gmp-requirements-for-atmps.html https://atmp.gmp-compliance.org/news/news-detail/what-are-the-gmp-requirements-for-biotechnological-products.html https://atmp.gmp-compliance.org/news/news-detail/latest-fda-updates-biosimilar-development-guidance.html https://atmp.gmp-compliance.org/news/news-detail/eca-atmp-group-publishes-position-paper-on-specifications-considering-patient-centricity.html https://atmp.gmp-compliance.org/news/news-detail/become-a-speaker-at-pharmalab-2026-analytic-bioanalytic-microbiology.html https://atmp.gmp-compliance.org/news/news-detail/eca-extends-special-pharmacongress-offer-3-for-1.html https://atmp.gmp-compliance.org/news/news-detail/utility-of-comparative-efficacy-studies-in-biosimilar-development.html https://atmp.gmp-compliance.org/news/news-detail/mat-survey-by-the-british-nc3rs.html https://atmp.gmp-compliance.org/news/news-detail/atmp-group-developments-from-may-to-august-2025.html https://atmp.gmp-compliance.org/news/news-detail/who-guidelines-on-reducing-animal-testing.html https://atmp.gmp-compliance.org/news/news-detail/standardisation-of-monoclonal-antibodies-mabs-by-the-epc.html https://atmp.gmp-compliance.org/news/news-detail/usp-publishes-revision-of-chapter-111-design-and-analysis-of-biological-assays.html https://atmp.gmp-compliance.org/news/news-detail/usp-chapter-1049-1-stability-studies-for-biotechnological-and-biological-products.html https://atmp.gmp-compliance.org/news/news-detail/usp-veroeffentlicht-revision-der-kapitels-111-design-and-analysis-of-biological-assays.html https://atmp.gmp-compliance.org/news/news-detail/microbiological-updates-of-the-pharmacopoeias.html https://atmp.gmp-compliance.org/news/news-detail/atmp-group-developments-from-january-to-april-2025.html https://atmp.gmp-compliance.org/news/news-detail/fda-initiates-transition-to-non-animal-testing-methods-for-monoclonal-antibodies.html https://atmp.gmp-compliance.org/news/news-detail/ema-proposes-revisions-to-gmp-guideline-for-atmps.html https://atmp.gmp-compliance.org/news/news-detail/microbiology-edqm-asks-for-comments-on-the-new-or-revised-chapters.html https://atmp.gmp-compliance.org/news/news-detail/fda-leitet-uebergang-zu-tierversuchsfreien-testmethoden-bei-mabs-ein.html https://atmp.gmp-compliance.org/news/news-detail/development-of-a-risk-based-quality-system-for-cmc-r-d-laboratories-in-drug-development.html https://atmp.gmp-compliance.org/news/news-detail/europaeische-pharmakopoee-kommission-verabschiedet-erste-allgemeine-texte-zu-mrna-impfstoffen.html https://atmp.gmp-compliance.org/news/news-detail/ema-guideline-on-quality-non-clinical-and-clinical-requirements-for-investigational-medicinal-products-for-advanced-therapies-in-clinical-trials.html https://atmp.gmp-compliance.org/news/news-detail/european-pharmacopoeia-commission-adopts-first-general-texts-on-mrna-vaccines.html https://atmp.gmp-compliance.org/news/news-detail/fda-warning-letter-unlicensed-biological-product-misbranding-and-many-other-offences.html https://atmp.gmp-compliance.org/news/news-detail/become-a-speaker-at-pharmalab-2025-analytics-bioanalytics-microbiology-and-more.html https://atmp.gmp-compliance.org/news/news-detail/14-submissions-for-the-professor-wallhaeusser-award-for-innovations-in-gmp-and-pharmaceutical-technology-2025.html https://atmp.gmp-compliance.org/news/news-detail/ema-leitlinie-zu-qualitaets-nichtklinischen-und-klinischen-anforderungen-fuer-pruefpraeparate-bei-atmps.html https://atmp.gmp-compliance.org/news/news-detail/fda-publishes-updated-guidance-on-the-accelerated-drug-approval-process-for-serious-diseases.html https://atmp.gmp-compliance.org/news/news-detail/recommendations-for-determining-the-suitability-of-donors-for-human-cells-tissues-and-cell-based-products-hct-ps.html https://atmp.gmp-compliance.org/news/news-detail/ema-q-a-when-is-testing-for-endotoxin-masking-effects-necessary-for-biological-products.html https://atmp.gmp-compliance.org/news/news-detail/fda-warning-letter-missing-licence-and-other-cgmp-violations-for-biologicals.html https://atmp.gmp-compliance.org/news/news-detail/revision-of-usp-chapter-1071-on-rapmethods-and-its-effect-on-other-usp-chapters.html https://atmp.gmp-compliance.org/news/news-detail/revision-of-usp-1032-design-and-development-of-biological-assays.html https://atmp.gmp-compliance.org/news/news-detail/publication-of-three-fda-draft-guidelines-on-donor-eligibility-for-hct-ps.html https://atmp.gmp-compliance.org/news/news-detail/revision-of-usp-1085-guidelines-on-endotoxin-test.html https://atmp.gmp-compliance.org/news/news-detail/inadequate-classification-leads-to-warning-letter.html https://atmp.gmp-compliance.org/news/news-detail/warning-letter-for-an-american-manufacturer-of-blood-products.html https://atmp.gmp-compliance.org/news/news-detail/supporting-biopharmaceutical-research-and-development-for-europe.html https://atmp.gmp-compliance.org/news/news-detail/revision-of-usp-chapter-1047-on-gene-therapy-medicinal-products.html https://atmp.gmp-compliance.org/news/news-detail/usp-follows-the-3r-principle-implementation-of-new-chapter-on-recombinant-test-methods.html https://atmp.gmp-compliance.org/news/news-detail/fda-developments-on-biosimilars.html https://atmp.gmp-compliance.org/news/news-detail/revision-of-usp-chapter-1033-on-validation-of-biological-assays-published.html https://atmp.gmp-compliance.org/news/news-detail/next-generation-of-genome-editing.html https://atmp.gmp-compliance.org/news/news-detail/a-further-step-for-the-soho-regulation.html https://atmp.gmp-compliance.org/news/news-detail/update-of-guideline-on-epidemiological-data.html https://atmp.gmp-compliance.org/news/news-detail/final-approval-of-soho-regulation.html https://atmp.gmp-compliance.org/news/news-detail/fda-warning-letter-to-a-biotechnology-company-in-china.html https://atmp.gmp-compliance.org/news/news-detail/hts-ngs-draft-ph-eur-chapter-high-throughput-sequencing-for-detecting-viral-extraneous-agents.html https://atmp.gmp-compliance.org/news/news-detail/fda-warning-letter-on-misbranded-and-unapproved-drugs.html https://atmp.gmp-compliance.org/news/news-detail/new-regulation-on-blood-blood-products-and-plasma.html https://atmp.gmp-compliance.org/news/news-detail/ema-and-fda-publish-q-a-document-on-their-accelerated-approval-programmes.html https://atmp.gmp-compliance.org/news/news-detail/fda-draft-guidance-on-potency-assays-for-cellular-and-gene-therapy-products.html https://atmp.gmp-compliance.org/news/news-detail/edqms-new-reference-substance-for-hepatitis-c-virus.html https://atmp.gmp-compliance.org/news/news-detail/new-guideline-on-haemotherapy.html https://atmp.gmp-compliance.org/news/news-detail/ema-revises-guidance-on-development-production-characterization-and-specification-for-monoclonal-antibodies-and-related-products.html https://atmp.gmp-compliance.org/news/news-detail/usp-briefing-on-mass-spectrometry-based-multi-attribute-method-for-therapeutic-proteins.html https://atmp.gmp-compliance.org/news/news-detail/emas-questions-and-answers-on-the-biological-medicines-marketing-authorisation-dossier-published.html https://atmp.gmp-compliance.org/news/news-detail/fda-recommendations-regarding-cgt-products.html https://atmp.gmp-compliance.org/news/news-detail/publication-of-ema-document-on-the-establishment-of-a-guideline-on-mrna-vaccines.html https://atmp.gmp-compliance.org/news/news-detail/potential-assays-for-monoclonal-antibodies-and-other-therapeutic-proteins.html https://atmp.gmp-compliance.org/news/news-detail/2nd-version-of-the-usp-draft-guidance-on-mrna-based-therapeutics.html https://atmp.gmp-compliance.org/news/news-detail/artificial-intelligence-machine-learning-in-the-analysis-of-biotherapeutics.html https://atmp.gmp-compliance.org/news/news-detail/transmission-of-malaria-by-blood-donors-fda-updates-guidance-document.html https://atmp.gmp-compliance.org/news/news-detail/fda-information-on-bacterial-contamination-of-platelets-for-transfusion.html https://atmp.gmp-compliance.org/news/news-detail/pyrogenicity-testing-european-pharmacopoeia-continues-to-be-updated.html https://atmp.gmp-compliance.org/news/news-detail/cmc-fda-publishes-guideline-with-questions-on-post-approval-modification-of-single-use-materials.html https://atmp.gmp-compliance.org/news/news-detail/fda-guidance-for-chimeric-antigen-receptor-car-t-cell-products.html https://atmp.gmp-compliance.org/news/news-detail/fda-revises-recommendations-on-investigational-cov19-covalescent-plasma.html https://atmp.gmp-compliance.org/news/news-detail/genome-editing-in-gene-therapy-fda-draft-guidance-for-ind.html https://atmp.gmp-compliance.org/news/news-detail/fda-updates-information-on-bacterial-contamination-of-platelets-for-transfusion.html https://atmp.gmp-compliance.org/news/news-detail/final-ema-guidelines-on-quality-requirements-for-imps.html https://atmp.gmp-compliance.org/news/news-detail/fda-guidance-on-cmc-change-management-for-biologics-and-notifications-published.html https://atmp.gmp-compliance.org/news/news-detail/fda-q-a-guidance-on-the-implementation-of-a-pathogen-reduction-system-for-blood-products.html https://atmp.gmp-compliance.org/news/news-detail/fda-sends-once-again-untitled-letter-to-manufacturers-of-regenerative-therapies.html https://atmp.gmp-compliance.org/news/news-detail/apic-update-of-the-ich-q7-how-to-do-document.html https://atmp.gmp-compliance.org/news/news-detail/who-publishes-guidance-on-safe-production-and-quality-control-of-monoclonal-antibodies.html https://atmp.gmp-compliance.org/news/news-detail/cov19-vaccines-inspections-under-emergency-approvals-in-the-us.html https://atmp.gmp-compliance.org/news/news-detail/regenerative-medicine-advanced-therapy-rmat-fda-explains-which-products-fall-under-rmat.html https://atmp.gmp-compliance.org/news/news-detail/fda-admonishes-regenerative-therapies-manufacturer-in-untitled-letter.html https://atmp.gmp-compliance.org/news/news-detail/revision-of-the-pic-s-guidelines-for-atmps-and-biological-medicinal-products.html https://atmp.gmp-compliance.org/news/news-detail/fdas-strategies-for-bacterial-safety-of-platelets.html https://atmp.gmp-compliance.org/news/news-detail/inspection-of-biotechnological-manufacturers-pic-s-aim-updated.html https://atmp.gmp-compliance.org/news/news-detail/fda-testing-of-cells-and-tissues-donors-for-transferable-diseases.html https://atmp.gmp-compliance.org/news/news-detail/cat-monthly-report-on-atmps.html https://atmp.gmp-compliance.org/news/news-detail/modern-vaccines-and-platform-technologies-explained-in-an-understandable-way.html https://atmp.gmp-compliance.org/news/news-detail/fda-explains-background-of-emergency-use-authorizations-related-to-cov19-vaccines.html https://atmp.gmp-compliance.org/news/news-detail/new-fda-guidance-on-cellular-and-tissue-products-hct-ps-published.html https://atmp.gmp-compliance.org/news/news-detail/fda-publishes-information-and-reviews-of-biological-research-projects.html https://atmp.gmp-compliance.org/news/news-detail/fda-notification-of-deviations-in-cell-and-tissue-products.html https://atmp.gmp-compliance.org/news/news-detail/ema-public-meeting-on-cov19-vaccines.html https://atmp.gmp-compliance.org/news/news-detail/coronavirus-fdas-advice-for-the-donation-of-cells-tissue-and-products-based-on-them.html https://atmp.gmp-compliance.org/news/news-detail/serological-tests-for-htlv-viruses-by-blood-and-blood-components.html https://atmp.gmp-compliance.org/news/news-detail/updated-recommendations-for-reducing-the-risk-of-cjd-and-vcjd-by-blood-and-blood-components.html https://atmp.gmp-compliance.org/news/news-detail/endotoxin-and-pyrogen-testing-challenges-for-biotechnological-and-biopharmaceutical-products.html https://atmp.gmp-compliance.org/news/news-detail/second-chapter-of-ecas-microbiological-oos-ool-guideline-announced-for-may.html https://atmp.gmp-compliance.org/news/news-detail/ema-chmp-publishes-new-q-a-document-on-comparability-considerations-for-atmps.html https://atmp.gmp-compliance.org/news/news-detail/fda-publishes-questions-and-answers-on-pathogen-reduction-in-blood-components.html https://atmp.gmp-compliance.org/news/news-detail/final-guideline-on-gcp-for-atmps-published.html https://atmp.gmp-compliance.org/news/news-detail/evaluation-of-the-immunogenicity-of-therapeutic-protein-products-fda-scientists-developed-a-new-tool.html https://atmp.gmp-compliance.org/news/news-detail/fda-publishes-q-a-on-internal-standard-responses-in-chromatography-bioanalysis.html https://atmp.gmp-compliance.org/news/news-detail/atmp-from-third-countries-new-q-a-paper-on-batch-release-published.html https://atmp.gmp-compliance.org/news/news-detail/fdas-promotion-for-cell-and-tissue-products-the-trg-rapinquiry-program-trip.html https://atmp.gmp-compliance.org/news/news-detail/how-to-handle-possibly-lifesaving-oos-batches-of-atmp-a-question-that-concerns-manufacturers-and-authorities.html https://atmp.gmp-compliance.org/news/news-detail/transmission-of-multiresistant-microorganisms-during-transplantation.html https://atmp.gmp-compliance.org/news/news-detail/fda-keeps-an-eye-on-use-and-marketing-of-cell-and-tissue-products.html https://atmp.gmp-compliance.org/news/news-detail/atmps-in-combination-with-a-medical-device-qp-task-on-release.html https://atmp.gmp-compliance.org/news/news-detail/fda-issues-warning-letter-to-manufacturer-of-human-cells-tissue-or-cell-based-products.html https://atmp.gmp-compliance.org/news/news-detail/fda-publishes-inspection-report-for-cells-tissues-and-cell-products.html https://atmp.gmp-compliance.org/news/news-detail/ich-m10-draft-guideline-on-validation-of-bioanalytical-methods-published-for-public-comments.html https://atmp.gmp-compliance.org/news/news-detail/updated-information-about-the-risk-of-zika-virus-transmission-via-cells-and-tissues.html https://atmp.gmp-compliance.org/news/news-detail/brexit-omcl-release-decisions-still-valid.html https://atmp.gmp-compliance.org/news/news-detail/gene-therapeutics-fda-updates-requirements-for-cmc-information.html https://atmp.gmp-compliance.org/news/news-detail/transfusion-transfer-of-babesiosis-fda-draft-recommendations-for-risk-minimization.html https://atmp.gmp-compliance.org/news/news-detail/fda-draft-guidance-on-the-risk-of-bacterial-contamination-of-blood-platelets.html https://atmp.gmp-compliance.org/news/news-detail/products-with-genetically-modified-cells-draft-guideline.html https://atmp.gmp-compliance.org/news/news-detail/false-positive-htlv-testing-recommendations-for-donor-requalification.html https://atmp.gmp-compliance.org/news/news-detail/viral-safety-of-blood-and-plasma-fda-guidance-on-hcv-testing.html https://atmp.gmp-compliance.org/news/news-detail/revision-fda-guideline-on-adaptive-designs-for-clinical-trials.html https://atmp.gmp-compliance.org/news/news-detail/fda-guidance-on-efficient-clinical-trial-design-strategies-for-cancer-drugs-and-biologics.html https://atmp.gmp-compliance.org/news/news-detail/gcp-for-atmp-stakeholder-consultation-on-the-draft-guideline.html https://atmp.gmp-compliance.org/news/news-detail/the-increasing-importance-of-gene-therapies-fda-statement-and-new-guidelines.html https://atmp.gmp-compliance.org/news/news-detail/european-commission-publishes-revised-version-of-eu-gmp-guideline-annex-2.html https://atmp.gmp-compliance.org/news/news-detail/ema-committee-for-advanced-therapies-cat-publishes-2018-work-plan.html https://atmp.gmp-compliance.org/news/news-detail/cat-and-chmp-update-their-procedural-advice-on-the-evaluation-of-atmps.html https://atmp.gmp-compliance.org/news/news-detail/ema-releases-draft-guideline-on-safety-and-efficacy-follow-up-and-risk-management-of-atmps.html https://atmp.gmp-compliance.org/news/news-detail/fda-draft-guideline-on-reporting-changes-to-an-approved-application.html https://atmp.gmp-compliance.org/news/news-detail/fda-revises-guideline-on-hiv-and-hcv-testing-for-the-assessment-of-blood-donors.html https://atmp.gmp-compliance.org/news/news-detail/ema-publishes-concept-paper-on-revision-of-the-guideline-on-clinical-development-of-vaccines.html https://atmp.gmp-compliance.org/news/news-detail/ema-publishes-first-guidance-for-stem-cell-therapies-in-animals.html https://atmp.gmp-compliance.org/news/news-detail/gmp-for-atmp-european-commission-adopts-new-guideline.html https://atmp.gmp-compliance.org/news/news-detail/edqm-publishes-guidance-for-root-cause-analysis-of-non-satisfactory-external-quality-assessment-results.html https://atmp.gmp-compliance.org/news/news-detail/guideline-for-medicinal-products-containing-genetically-modified-cells-ema-plans-revision.html https://atmp.gmp-compliance.org/news/news-detail/guidance-for-industry-transmission-risk-of-west-nile-virus-from-living-donors-of-cells-and-tissues.html https://atmp.gmp-compliance.org/news/news-detail/pic-s-statement-to-european-commissions-atmp-gmp-guideline.html https://atmp.gmp-compliance.org/news/news-detail/ongoing-developments-in-the-field-of-atmp.html https://atmp.gmp-compliance.org/news/news-detail/gmp-for-atmp-two-public-rounds-of-consultation-and-still-a-need-for-discussion.html https://atmp.gmp-compliance.org/news/news-detail/european-commission-draft-guideline-gmp-for-atmp-open-for-stakeholder-consultation.html https://atmp.gmp-compliance.org/news/news-detail/edqm-survey-on-new-general-chapter-on-microbiological-control-of-tissue.html https://atmp.gmp-compliance.org/news/news-detail/zika-virus-reducing-the-risk-of-transmission-of-zika-virus-by-human-cells-tissues-and-cellular-and-tissue-based-products.html https://atmp.gmp-compliance.org/news/news-detail/atmp-monthly-report-of-the-cat-january-2016.html https://atmp.gmp-compliance.org/news/news-detail/fda-draft-guidance-on-nat-tests-to-reduce-the-risks-of-hbv-transmission-from-cells-and-tissues.html https://atmp.gmp-compliance.org/news/news-detail/fda-publishes-draft-guidance-for-industry-deviation-reporting-for-human-cells-tissues-and-cellular-and-tissue-based-products.html https://atmp.gmp-compliance.org/news/news-detail/guidance-for-treponema-pallidum-screening-of-donors-of-human-cells-and-tissues-hct-ps.html https://atmp.gmp-compliance.org/news/news-detail/fda-issues-draft-guidance-on-homologous-use-of-human-cells-tissues-and-cellular-and-tissue-based-products.html https://atmp.gmp-compliance.org/news/news-detail/european-pharmacopoeia-chapter-2-6-27-microbiological-examination-of-cell-based-preparations-revised.html https://atmp.gmp-compliance.org/news/news-detail/cber-considerations-for-the-design-of-early-phase-clinical-trials-of-cellular-and-gene-therapy-products.html https://atmp.gmp-compliance.org/news/news-detail/fda-guidances-investigating-and-reporting-adverse-reactions-related-to-human-cells-tissues-and-cellular-and-tissue-based-products.html https://atmp.gmp-compliance.org/news/news-detail/human-cells-tissues-or-cellular-or-tissue-based-products-exception-from-the-requirements-under-part-1271.html https://atmp.gmp-compliance.org/news/news-detail/fda-publishes-draft-guidance-for-minimal-manipulation-of-human-cells-tissues-and-cellular-and-tissue-based-products.html https://atmp.gmp-compliance.org/news/news-detail/nat-testing-of-west-nile-virus-from-human-cells-and-tissues.html https://atmp.gmp-compliance.org/news/news-detail/approval-of-combined-advanced-therapy-product.html https://atmp.gmp-compliance.org/news/news-detail/risk-based-approach-to-advanced-therapy-medicinal-products.html https://atmp.gmp-compliance.org/news/news-detail/ema-announces-streamlining-of-activities-of-committee-for-advanced-therapies.html https://atmp.gmp-compliance.org/news/news-detail/commitee-for-advanced-therapy-medicinal-products-cat-public-call-for-expression-of-interest.html https://atmp.gmp-compliance.org/news/news-detail/atmp-ema-reflection-paper-on-classification-of-advanced-therapy-medicinal-products.html https://atmp.gmp-compliance.org/news/news-detail/ema-position-statement-on-creutzfeldt-jakob-disease-and-advanced-therapy-medicinal-products.html